See the DrugPatentWatch profile for vevye
What Is Vevye and What Does the FDA Say About Its Safety?
Vevye (cyclosporine ophthalmic solution 0.1%) is an FDA-approved eye drop for treating signs and symptoms of dry eye disease in adults. The agency approved it in February 2023 based on clinical trials showing efficacy and an acceptable safety profile, classifying it as a cationic emulsion nanoemulsion—a novel formulation of cyclosporine that avoids preservatives found in older versions like Restasis.[1]
What Side Effects Do Patients Report?
Common side effects include eye irritation (up to 13% of users), instillation site pain (12%), and blurred vision (9%). Less frequent issues are headache (5%) and urinary tract infections (3%). These are mostly mild and resolve without intervention. Severe reactions are rare, with no anaphylaxis or vision-threatening events reported in pivotal trials involving over 1,300 patients.[1][2]
How Does Vevye Compare to Restasis for Safety?
Vevye uses a water-free emulsion, eliminating preservatives like benzalkonium chloride that can worsen dry eye in Restasis users. Trials showed Vevye caused less ocular burning (6% vs. 13% for Restasis) and surface staining, making it potentially better tolerated for sensitive eyes. Both carry black-box warnings for potential eye infections if contaminated, but Vevye's single-use vials reduce this risk.[1][3]
Are There Long-Term Safety Concerns or Risks?
No long-term data beyond 12 weeks from approval trials exists yet, but cyclosporine has decades of ophthalmic use with no evidence of systemic absorption causing immunosuppression. Risks include delayed healing if used with contact lenses (remove before dosing) and avoiding in active eye infections. Pregnant or breastfeeding patients should consult doctors due to limited data.[1][2]
Who Should Avoid Vevye?
Contraindicated in those with hypersensitivity to cyclosporine or its components. Use caution with neovascular glaucoma or infections. No pediatric approval; not studied in kids under 18.[1]
[1]: FDA Prescribing Information for Vevye
[2]: Harrow Inc. Clinical Trial Data
[3]: Ophthalmology Times Comparison